Enrollment Form Cervical (CESC)

Instructions: The Enrollment Form should be completed for each TCGA qualified case, upon qualification notice from the BCR. All information provided on this form should include activity from the date of initial diagnosis to the most recent date of contact with the patient ("Date of Initial Pathologic Diagnosis" and "Date of Last Contact" on this form).

Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.

Please note the following definitions for the "Unknown" and "Not Evaluated" answer options on this form.

Unknown: This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the TCGA required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

Not Evaluated: This answer option should only be selected by the TSS if it is known that the information being requested cannot be obtained. This could be because the test in question was never performed on the patient or the TSS knows that the information requested was never disclosed.

Tissue Source Site (TSS): ______TSS Identifier: _____TSS Unique Patient Identifier: _____

Completed By (Interviewer Name in OpenClinica): _____

General Information				
#	Data Element	Entry Alternatives	Working Instructions	
1	Has this TSS received permission from the NCI to provide time intervals as a substitute for requested dates on this form?	□ Yes □ No	If the answer to this question is yes, time intervals must be provided instead of dates, as indicated throughout this form. Provided time intervals must begin with the date of initial pathologic diagnosis (e.g. biopsy). Only provide interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.	
2	Is this a prospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for prospective tissue collection. If the submitted tissue was collected for the specific purpose of TCGA, the tissue has been collected prospectively. <u>3088492</u>	
3	Is this a retrospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for retrospective tissue collection. If the submitted tissue was collected prior to the date the TCGA contract was executed, the tissue has been collected retrospectively. <u>3088528</u>	

Patient Information

#	Data Element	Entry Alternatives	Working Instructions
4	Date of Birth	/// (month) (day) (year)	Provide the date the patient was born. <u>2896950</u> (month), <u>2896952</u> (day), <u>2896954</u> (year) <i>Note: The day of Birth is not required.</i>
5	Number of Days from Date of Initial Pathologic Diagnosis to Date of Birth		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the patient's date of birth. <u>3008233</u> Only provide Interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
6	Gender	☐ Female ☐ Male	Provide the patient's gender using the defined categories. 2200604

_Completed Date: _____

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alternatives	Working Instructions
7	Menopause Status (at time of diagnosis)	 Premenopausal G months since LMP AND no prior bilateral oophorectomy AND not on estrogen replacement Perimenopausal G-12 months since last menstrual period Postmenopausal Prior bilateral oophorectomy OR >12 months since LMP with no prior oophorectomry Indeterminate or Unknown Not Evaluated 	Using the patient's medical records, indicate menopause status at the time the patient was diagnosed with the malignancy submitted for TCGA. 2957270
8	Height (at time of diagnosis)	(cm)	Provide the patient's height (in centimeters) at the time the patient was diagnosed with the malignancy being submitted for TCGA. <u>649</u>
9	Weight (at time of diagnosis)	(kg)	Provide the patient's weight (in kilograms) at the time the patient was diagnosed with the malignancy being submitted for TCGA. <u>651</u>
10	Race	 American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. Asian A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. White A person having origins in any of the original peoples of the far Europe, the Middle East, or North Africa. Black or African American A person having origins in any of any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American." Native Hawaiian or other Pacific Islander: A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. Not Evaluated Not provided or available. Unknown Could not be determined or unsure. 	Provide the patient's race using the defined categories. 2192199
11	Ethnicity	 Not Hispanic or Latino: A person not meeting the definition of Hispanic or Latino. Hispanic or Latino: A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Evaluated Not provided or available. Unknown	Provide the patient's ethnicity using the defined categories. 2192217

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alternatives	Working Instructions
12	History of Prior Malignancy	□ Yes □ No	Indicate whether the patient was, at any time in their life, diagnosed with a malignancy prior to the diagnosis of the specimen submitted for TCGA. If the patient has had a prior malignancy, an additional form (the "Other Malignancy Form") must be completed for each prior malignancy. If the OMF was completed and submitted with the Initial Case Quality Control Form, the OMF does not need to be submitted a second time. <u>3382736</u> If this question cannot be answered because the answer is
			unknown, the case will be excluded from TCGA. If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.
13	History of Neo-adjuvant Treatment for Sample Submitted for TCGA	□ Yes □ No	Indicate whether the patient received neo-adjuvant treatment (radiation, pharmaceutical, or both) prior to the collection of the sample submitted for TCGA. <u>3382737</u> Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted sample) given prior to the collection of the sample submitted for TCGA is exclusionary.
14	Tumor Status (at time of last contact or death)	☐ Tumor free☐ With tumor☐ Unknown	Indicate whether the patient was tumor/disease free at the date of last contact or death. 2759550
15	Vital Status (at date of last contact)	□ Living □ Deceased	Indicate whether the patient was living or deceased at the date of last contact. 2939553
16	Date of Last Contact	/// (month) (day) (year)	If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver). <u>2897020</u> (month), <u>2897022</u> (day), <u>2897024</u> (year) <i>Note:</i> Do not answer if patient is deceased. <i>The day of Last Contact is not required</i> .
17	Number of Days from Date of Initial Pathologic Diagnosis to Date of Last Contact		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of last contact. <u>3008273</u> Only provide Interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
18	Date of Death	/// (month) (day) (year)	If the patient is deceased, provide the month of death. <u>2897026</u> , (month) <u>2897028</u> (day), <u>2897030</u> (year) <i>Note: The day of Death is not required</i> .
19	Number of Days from Date of Initial Pathologic Diagnosis to Date of Death		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of death. <u>3165475</u> Only provide Interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
20	Cause of Death	 Cervical cancer Other cause(s), specify Unknown 	Indicate the patient's cause of death. <u>2554674</u>
21	Other Cause of Death		If the patient's cause of death was not included in the provided list, specify the patient's cause(s) of death. <u>2004150</u>
Hist	ory of Pregnancies and (-	
22	Use of Hormonal Contraceptives	 Current User Former User Never Used Unknown 	Indicate whether the patient has used or is currently using hormonal contraceptives. <u>3104217</u>

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alt	ternatives	Working Instructions
23	Total Number of Pregnancies			Provide the total number of times the patient conceived and became pregnant. This should include all of the pregnancies under the question "Number of Pregnancies by Outcome Type" and current pregnancies. 2005341
		Pregnancy Type	Number of Pregnancies	
		Live Birth (single or multiple births)		Provide the number of times the patient had successful pregnancies that resulted in the live birth of at least one child. <u>2005342</u>
		Miscarriage		Provide the number of times the patient conceived and became pregnant, but did not carry fetus to term due to natural occurrences or problems during the pregnancy. <u>2180637</u>
24	Number of Pregnancies by Outcome Type	Induced Abortion		Provide the number of times the patient conceived and became pregnant, but did not carry fetus to term due to medical intervention to end the pregnancy. <u>2180648</u>
	(Complete all that apply)	Ectopic Pregnancy		Provide the number of times the patient conceived and become pregnant, but did not carry the fetus to term due to an ectopic pregnancy. 2261915
		Stillbirth (early fetal death)		Indicate the number of times the patient conceived and become pregnant, but the pregnancy ended with stillbirth. <u>2183304</u>
		Unknown		Provide the number of times the patient was known to be pregnant, but the outcome of the pregnancy was unknown.
25	Pregnant at Time of	□ Yes		Indicate whether the patient was pregnant at the time of initial diagnosis.
23	Diagnosis	🗖 No		3012573
Smo	oking History			
26	Tobacco smoking history indicator	 □ Lifelong non-smoke smoked in lifetime) □ Current smoker (ind daily smokers) □ Current reformed sn specified) □ Current reformed sn □ Current reformed sn □ Current reformed sn □ Smoking History no 	cludes daily and non- moker (duration not moker for > 15 years noker for <= 15 years	Indicate the patient's history of tobacco smoking as well as their current smoking status using the defined categories. If the patient is a lifelong non-smoker, skip the additional smoking questions. <u>2181650</u>
27	Age of onset tobacco smoking	Years of Age		Provide the age in years when the patient began smoking cigarettes. <u>2178045</u> If the patient is a lifelong non-smoker, do not answer this question.
28	Year of quitting tobacco smoking	(YYYY)		Provide the year the patient quit smoking. <u>2228610</u> If the patient is a lifelong non-smoker or if the patient has not quit smoking, do not answer this question.
29	Number of Pack Years Smoked		_Years	Provide the number of pack years the patient smoked. This is calculated using the number of cigarettes smoked per day times the number of years smoked, divided by 20. For example, if a patient smoked 5 cigarettes per day times 10 years divided by 20, the patient would have 2.5 pack years (e.g. 5 x 10/ 20=2.5). 2955385
				If the patient is a lifelong non-smoker, do not answer this question.
Hist	ory of Immunosuppress	ive Disease		

Enrollment Form

Cervical (CESC))
-----------------	---

#	Data Element	Entry Alternatives	Working Instructions	
30	History of Immunosuppressive Disease (Check all that apply)	 HIV Organ Transplant Chronic Systemic Steroid Use Unknown Not Evaluated Other, specify 	If the patient has had any history of immunosuppressive disease(s), provide the patient's medical history. If the patient's disease is not provided in the list, select "other" and provide the specific disease in the following question. <u>3151446</u>	
31	Other Immunosuppressive Disease		Specify any history of immunosuppressive disease that is not included in the list provided. <u>3151449</u>	
Per	formance Status and Mea	asure of Success		
32	Performance Status: Eastern Cooperative Oncology Group (ECOG)	 0 - Asymptomatic 1 - Symptomatic but fully ambulatory 2 - Symptomatic but in bed less than 50% of the day 3 - Symptomatic and in bed more than 50% of the day 4 - Bedridden 	Using the patient's medical records, provide the ECOG performance status score at the time provided in the following question. 88 88	
33	Performance Status: Timing	 Preoperative Pre-adjuvant therapy Post-adjuvant therapy Other, specify 	Indicate the time point of the documented ECOG performance score provided above. 2792763	
34	Other Performance Status Scale: Timing		If the status of the patient during the last documented ECOG performance score was not included in the provided list, specify the patient's status. 3151756	
35	Date of Performance Status	(month) (day) (year)	Provide the date of the last documented ECOG performance score. <u>3121370</u> (month), <u>3121372</u> (day), <u>3121374</u> (year) <i>Note: The day of Performance Status is not required.</i>	
36	Measure of success of outcome <u>at the</u> <u>completion of initial</u> <u>first course treatment</u> (including surgery)	 Progressive Disease Stable Disease Partial Response Complete Response Unknown Not Applicable (Treatment Ongoing) 	Indicate the patient's measure of success after their primary treatment including surgery and adjuvant therapies. <u>2786727</u>	
Pathologic/Prognostic Information				

#	Data Element	Entry Alternatives	Working Instructions
Patl	hologic Diagnosis Inform	ation	
37	Primary Site of Disease	Cervix	Using the patient's pathology/laboratory report, select the anatomic site of disease of the tumor submitted for TCGA. <u>2735776</u>
38	Histological Subtype	 Cervical Squamous Cell Carcinoma Endocervical type of Adenocarcinoma Endocervical Adenocarcinoma of the Usual Type Mucin-depleted Adenocarcinoma Endometrioid Adenocarcinoma of Endocervix Mucinous Adenocarcinoma of Endocervical Type Adenosquamous Carcinoma 	Using the patient's pathology/laboratory report, select the histology of the tumor submitted for TCGA. <u>3081934</u>
39	Keratinization in Squamous Cell Carcinoma	 Keratinizing squamous cell carcinoma Non-keratinizing squamous cell carcinoma 	If the patient had squamous cell carcinoma, indicate whether the tumor has any keratinizing squamous cell carcinoma using the patient's pathology/laboratory report. Keratinizing tumors have at least one well-formed keratin pearl. All other patters are non-keratinizing. <u>3151599</u>

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alternatives	Working Instructions
40	Tumor Grade	 G1 Well Differentiated G2 Moderately Differentiated G3 Poorly Differentiated G4 Undifferentiated GX Grade cannot be assessed 	Using the patient's pathology/laboratory report, select the tumor grade. <u>2785839</u>
41	Date of Initial Pathologic Diagnosis	/// (month) (day) (year)	Provide the date the patient was initially pathologically diagnosed with the malignancy submitted for TCGA. <u>2896956</u> (month), <u>2896958</u> (day), <u>2896960</u> (year) Note: The day of Initial Pathologic Diagnosis is not required.
42	Age at Initial Diagnosis		Provide the age of the patient in years, at the time the patient was initially pathologically diagnosed. <u>2006657</u> Only complete this question if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
43	Method of Initial Pathologic Diagnosis	 Cytology Biopsy (cervical, CT-guided or other) Cone biopsy/ LEEP Lymph node sampling or dissection Other, specify 	Provide the procedure used to initially diagnose the patient. <u>2757941</u> Please note that this method is referring to the procedure performed on the Date of Initial Pathologic Diagnosis, provided in the previous question.
44	Other Method of Pathologic Diagnosis		If the procedure used to initially diagnose the patient was not included in the list provided, please describe the method used. <u>2757948</u>
45	If hysterectomy was performed, what type was it?	 Hysterectomy not performed Simple Radical (modified or not modified) Other, specify 	Indicate whether a hysterectomy was performed at diagnosis. If a hysterectomy was performed, indicate the type. <u>2647164</u>
46	Other Type of Hysterectomy		If the type of hysterectomy performed was not included in the list provided, please provide the type of hysterectomy performed. <u>3151506</u>
47	If hysterectomy was performed, were there involved pathologic margins?	 Macroscopic parametrial involvement Microscopic parametrial involvement Positive bladder margin Positive vaginal margin Unknown Other, specify 	If a hysterectomy was performed, provide the patient's margin involvement after surgery. 3151541
48	Other Involved Pathologic Margins		If the margin involvement was not included in the provided list, describe the pathologic margins. <u>3151544</u>
49	Pelvic Extension Comment		Using the patient's pathology/laboratory report, provide comments regarding any tumor extension to the pelvic wall. 3151605
50	Pathologic Lymphovascular Invasion	 Present Absent Unknown 	Using the patient's pathology/laboratory report, indicate the presence or absents of pathologic lymphovascular invasion. 2008052
51	Corpus Involvement	 Present Absent Unknown 	The corpus uteri is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ. To have a connection by participation or association or use; sharing in an activity or process. 3151610
Lyn	iph Node Status		
52	Were Lymph Nodes Examined at the Time of Primary Resection?	□ Yes □ No □ Unknown	Indicate whether any lymph nodes were examined at the time of the primary resection. 2200396
53	Number of Lymph Nodes Examined		Provide the number of lymph nodes examined, if one or more lymph nodes were removed. 3
54	Number of Lymph Nodes Positive by H&E		Provide the number of lymph nodes positive through hematoxylin and eosin (H&E) staining and light microscopy.

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alternatives	Working Instructions
	light microscopy		3086388
55	Number of Lymph Nodes Positive by IHC Keratin Staining only		Provide the number of lymph nodes positive through keratin immunohistochemistry (IHC) staining. <u>3086383</u>
56	Pathologic Positive Lymph Node Location(s) (Check all that apply)	 Pelvic (external iliac, internal iliac, obturator) Common iliac Paraaortic Supraclavicular Unknown Other, specify 	Using the patient's pathology/laboratory report, provide the location(s) of any positive lymph nodes. <u>3151519</u>
57	Other Positive Lymph Node		If the location of positive lymph nodes was not included in the list provide, please provide the location of positive lymph nodes. 3151522
AJC	C Staging		
58	AJCC Cancer Staging Edition	 1st Edition (1978-1983) 2nd Edition (1984-1988) 3rd Edition (1989-1992) 4th Edition (1993-1997) 5th Edition (1998-2002) 6th Edition (2003-2009) 7th Edition (2010-present) 	Please select the AJCC Cancer Staging Edition used to answer the following questions. 2722309
59	Pathologic Spread: Primary Tumor (pT)	TX T1b T2a2 T0 T1b1 T2b Tis T1b2 T3 T1 T2 T3a T1a T2a T3b T1a1 T2a1 T4 T1a2 T3a T4	Using the patient's pathology/laboratory report, select the code for the pathologic T (primary tumor) defined by the American Joint Committee on Cancer (AJCC). <u>3045435</u>
60	Pathologic Spread: Regional Nodes (pN)	□ NX □ N0 □ N1	Using the patient's pathology/laboratory report, select the code for the pathologic N (nodal) defined by the American Joint Committee on Cancer (AJCC). 3203106
61	Pathologic Distant Spread: Distant Metastasis (M)	□ MX □ M0 □ M1	Using the patient's pathology/laboratory report, select the code for the pathologic M (metastasis) defined by the American Joint Committee on Cancer (AJCC). <u>3045439</u>
62	FIGO Staging System (Publication Date Used for Staging)	□ 1988 □ 1995 □ 2009	Using the patient's pathology/laboratory report, provide the FIGO staging system used to stage the patient. <u>3114049</u>
63	FIGO Stage	Stage IStage IIA1Stage IAStage IIA2Stage IA1Stage IIBStage IA2Stage IIIStage IBStage IIIAStage IB1Stage IIBStage IB2Stage IVStage IIAStage IVAStage IIAStage IVB	Using the patient's pathology/laboratory report, provide the FIGO stage given to the patient at the time of diagnosis. 3225684
Tests	Performed		
64	Date of FED-PET or PET / CT	///	If the patient's medical records indicate the patient had a FED- PET or PET/CT, provide the month of the FED-PET or PET/CT. <u>3151498 (month)</u> , <u>3151499</u> (day), <u>3151500</u> (year)

Enrollment Form Cervical (CESC)

65	Cervix SUV Results					If the patient's medical records indicate the patient had a FED- PET or PET/CT, provide the cervix standardized update value (SUV). <u>3151615</u>
66	FED-PET or PET / CT Results (Check all that apply)	Anatomic Site Pelvic Nodes Paraaortic Nodes Supraclavicular Nodes Parametrium Bladder Extra-Pelvic Metastatic Disease	Present	Absent	Unknown	If the patient's medical records indicate the patient had a FED- PET or PET/CT, provide the results for each applicable anatomic site. <u>3151497</u>
67	Date of MRI	$\frac{1}{(\text{month})}$ / (da	/ y)	(year)		If the patient's medical records indicate the patient had an MRI, provide the date of the MRI. <u>3151491</u> (month), <u>3151492 (</u> day), <u>3151493</u> (year)
68	MRI Results (Check all that apply)	Anatomic Site Pelvic Nodes Paraaortic Nodes Supraclavicular Nodes Parametrium Bladder Extra-Pelvic Metastatic Disease	Present	Absent	Unknown 	If the patient's medical records indicate the patient had a MRI, provide the results for each applicable anatomic site. 3151441
69	Date of CT	///				If the patient's medical records indicate the patient had an MRI, provide the date of the MRI. <u>3151134</u> (month), <u>3151132 (</u> day), <u>3151133 (</u> year)
70	CT Results (Check all that apply)	Anatomic Site Pelvic Nodes Paraaortic Nodes Supraclavicular Nodes Parametrium Bladder Extra-Pelvic Metastatic Disease	Present	Absent	Unknown	If the patient's medical records indicate the patient had a CT, provide the results for each applicable anatomic site. <u>3151439</u>
71	HPV (List all types)	□ HPV 16 □ HPV 18	□ HPV 16 □ HPV 18 □ Other HPV Type			If the patient's medical records indicate human papillomavirus (HPV), provide the HPV type. <u>2922649</u>
72	Other HPV Type(s)					If the patient's medical records indicate human papillomavirus (HPV) and the type is not included in the provided list, please describe the HPV type. <u>3166168</u>
73	Method of HPV Typing	 PCR Qiagen-digene #C2 Roche - linear array Other (please specify) 				Indicate the method used for HPV typing. <u>3151457</u>
74	Other Method of HPV Typing					If the method used for HPV typing is not included in the provided list, please describe the method used. <u>3151460</u>
75	PCR Primer Pairs	 MY09/MY11 PGMY09/PGMY11 Roche - linear array SPF10-LiPA GP5+/GP6+ Other (please specify) 				Indicate the PCR primer pairs used. <u>3151487</u>

Page	9
	2

Enrollment Form С

Lervical (LESL)	Cervical	(CESC)
-----------------	----------	--------

76	Other PCR Primer Pairs		If the PCR primer pairs used are not included in the provided list, please describe the PCR primer pairs used. 3151490
77	Squamous Cellular Carcinoma Antigen (SCCA) Tumor Marke	μg/μL	Provide the patient's squamous cellular carcinoma antigen (SCCA) tumor marker results. 3151234
78	Date of SCCA Performed	///	Provide the date SCCA was performed. 3151235 (month), 3151236 (day), 3151237 (year)

Treatment Information

#	Data Element	Entry Alternatives	Working Instructions
79	Adjuvant (Post- Operative) Radiation Therapy	☐ Yes □ No □ Unknown	Indicate whether the patient had adjuvant/ post- operative radiation therapy. <u>2005312</u> If the patient did have adjuvant radiation, the Radiation Supplemental Form should be completed.
80	Adjuvant (Post- Operative) Pharmaceutical Therapy	□ Yes □ No □ Unknown	Indicate whether the patient had adjuvant/ post- operative pharmaceutical therapy. <u>3397567</u> If the patient did have adjuvant pharmaceutical therapy, the Pharmaceutical Supplemental Form should be completed.
Rad	iation Therapy (Brachyt	herapy and External Radiation)	
81	If patient did not complete radiation, provide the primary reason why it was not given or not completed.	 Adverse event/complications Scheduling problems Participant refusal Not done per treating physicians discretion Other, specify Unknown 	If the patient did not receive radiation indicate the reason treatment was not administered. <u>2733266</u>
82	Other Reason Radiation Not Given or Not Completed		If the reason the patient did not receive radiation is not included in the provided list, specify the reason. <u>2733267</u>
83	If patient received brachytherapy, indicate the type.	 LDR HDR Other, specify 	If the patient received brachytherapy, indicate the type administered. If the patient did not receive brachytherapy, skip all related questions. <u>2966127</u>
84	Other Type of Brachytherapy		If the type of brachytherapy the patient received is not included in the provided list, specify the type administered. <u>3150976</u>
85	If patient received brachytherapy, provide the total dose to point A.	cGy	Indicate the total dose (cGy) of brachytherapy to point A the patient received. <u>3151100</u>
86	If patient received external radiation provide type of external radiation	 3D Conformal IMRT External Beam Unknown Other, specify 	If the patient received external radiation, indicate the type administered. If the patient did not receive external radiation, skip all related questions. <u>61468</u>
87	Other Type of External Radiation		If the type of external radiation the patient received is not included in the provided list, specify the type administered. <u>2195477</u>
88	Total Dose to Pelvis/Pelvic Nodes	cGy	Indicate the total dose (cGy) of external radiation the patient received to pelvis/pelvic nodes. 3006
89	Total Dose to Paraaortic Nodes	cGy	Indicate the total dose (cGy) of external radiation the patient received to paraaortic nodes. <u>3151106</u>
Con	current Chemotherapy		

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alternatives	Working Instructions
90	Was chemotherapy given concurrent to radiation after tissue procurement?	☐ Yes □ No □ Unknown	Indicate whether the patient received chemotherapy concurrent to radiation treatment after tissue procurement. <u>2539220</u>
91	If patient did not complete chemotherapy concurrent to radiation, provide the primary reason why it was not given or not completed.	 Adverse event/complications Scheduling problems Participant refusal Not done per treating physicians discretion Other, specify Unknown 	If the patient did not receive chemotherapy concurrent to radiation treatment indicate the reason treatment was not administered. 3151120
92	Other Reason Chemotherapy Not Given concurrent to Radiation		If the reason the patient did not receive chemotherapy concurrent to radiation treatment is not included in the provided list, specify the reason. <u>3151824</u>
<u>93</u>	If patient received concurrent chemotherapy, indicate type of concurrent chemotherapy. (Check all that apply)	 Cisplatin Carboplatin Other, specify 	If the patient received chemotherapy concurrent to radiation treatment, indicate the type administered. If the patient did not receive external radiation, skip all related questions. <u>2007212</u>
<u>94</u>	Other Type of Concurrent Chemotherapy		If the type of chemotherapy given concurrent to radiation treatment is not included in the provided list, specify the type administered. 2426129
<u>95</u>	Concurrent Chemotherapy Dose		Indicate the dose of the concurrent chemotherapy the patient received. Include the unit of measure. <u>3166172</u> and <u>3065815</u>
<u>96</u>	Concurrent Chemotherapy Frequency	Every hourEvery 24 hours5 times dailyEvery other day4 times dailyTwice a week3 times dailyOnce weekly2 times dailyState of the second s	Indicate the frequency the concurrent chemotherapy was received. <u>2179580</u>
<u>97</u>	Concurrent Chemotherapy Number of Total Doses		Indicate the total number of doses the patient received the concurrent chemotherapy. <u>2180805</u>

New Tumor Event Information Complete this section if the patient had a new tumor event. If the patient did not have a new tumor event (or if the TSS does not know) indicate this in the question below, and the remainder of this section can be skipped.

#	Data Element	Entry Alternatives		Working Instructions
98	New Tumor Event After Initial Treatment?	☐ Yes □ No □ Unknown		Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after initial treatment. <u>3121376</u> If the patient did not have a new tumor event or if this is unknown, the remaining questions can be skipped.
<u>99</u>	Type of New Tumor Event	 Locoregional recurrence Distant Metastasis New Primary Tumor 		Indicate whether the patient's new tumor event was a locoregional recurrence, a distant metastasis or a new primary tumor. 3119721
<u>100</u>	Site of New Tumor Event	□ Cervix □ Head & Neck □ Lung □ Vulvar	 □ Anus □ Other, specify □ Unknown □ Not Applicable 	If the patient had a new tumor event, provide the site of this tumor. 3108271
<u>101</u>	Other Site of New Tumor Event			If the site of the new tumor event is not included in the provided list, describe the site of this new tumor event. 3128033

Enrollment Form Cervical (CESC)

#	Data Element	Entry Alternatives	Working Instructions
<u>102</u>	Date of New Tumor Event	///	If the patient had a new tumor event, provide the date of diagnosis for this new tumor event. <u>3104044 (month)</u> , <u>3104042</u> (day), <u>3104046</u> (year)
<u>103</u>	Number of Days from Date of Initial Pathologic Diagnosis to Date of New Tumor Event After Initial Treatment		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of new tumor event after initial treatment. <u>3392464</u> Only provide Interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
<u>104</u>	Method of Pathologic Diagnosis for New Tumor Event	 Cytology Tumor Resection Other, specify 	Indicate the method used to pathologically diagnose the new tumor event. <u>3151113</u>
<u>105</u>	Other Method of Pathologic Diagnosis for New Tumor Event		If the pathologic method used to diagnose the new tumor event is not included in the provided list, specify the method used. <u>3151116</u>
<u>106</u>	Additional Surgery for New Tumor Event	□ Yes □ No □ Unknown	Using the patient's medical records, indicate whether the patient had surgery for the new tumor event in question. 3427611
<u>107</u>	Date of Additional Surgery for New Tumor Event	///	If the patient had surgery for the new tumor event, provide the date this surgery was performed. <u>3427612</u> (month), <u>3427613</u> (day), <u>3427614</u> (year)
<u>108</u>	Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of additional surgery for new tumor event (loco-regional). <u>3008335</u> Only provide Interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
<u>109</u>	Residual Tumor After surgery for New Tumor Event	 RX: The presence of residual tumor or margin status cannot be assessed. R0: No residual tumor and negative microscopic margins in resected specimen. R1: Microscopic residual tumor. No gross residual disease but positive microscopic margins. R2: Macroscopic residual tumor. Grossly visible residual disease. 	Using the patient's pathology/laboratory report, select the residual tumor status after the surgical resection for the new tumor event. <u>3104061</u>
<u>110</u>	Additional treatment for New Tumor Event: <i>Radiation Therapy</i>	□ Yes □ No □ Unknown	Indicate whether the patient received radiation treatment for this new tumor event. <u>3427615</u>
<u>111</u>	Additional treatment for New Tumor Event: <i>Pharmaceutical Therapy</i>	□ Yes □ No □ Unknown	Indicate whether the patient received pharmaceutical treatment for this new tumor event. <u>3427616</u>

./. Date